Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Calamus has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
The pairing comes from traditional formulary rather than from any controlled comparison, and both are aromatic rhizomes used in the same role. Ginger has its own human evidence base; calamus does not have an equivalent one. Combining them does not transfer ginger's evidence to calamus. Read it as historical practice.
Both materials deliver their constituents as a volatile oil fraction, so they share extraction chemistry, formulation constraints and the tendency to lose potency to evaporation. Enteric coating and cool storage apply to both. The overlap is technical rather than physiological. Nothing here says the combination does anything a single one does not.
Volatile oil constituents oxidise over shelf life, and antioxidants are added to slow that. This is stabilising the material, not a physiological interaction. It matters for potency at the end of shelf life rather than for what happens after ingestion. This is formulation practice.
Beta-asarone undergoes hepatic metabolism, and its reported toxicity in animal work centres on the liver. That makes concurrent hepatic load the relevant consideration with any calamus material of unspecified chemotype. Nothing about pairing it with a liver-supportive botanical makes beta-asarone exposure acceptable. The correct response is a low-asarone chemotype or avoidance, not a companion ingredient.
Nothing specific on file for Calamus. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 1 we read for Calamus. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.